×
About 493 results

ALLMedicine™ Acute Graft Versus Host Disease Center

Research & Reviews  146 results

Genetic susceptibility to acute graft versus host disease in pediatric patients undergo...
https://doi.org/10.1038/s41409-021-01386-8 10.1182/blood-2010-01-261958 10.1200/JCO.2004.02.189 10.1038/bmt.2010.174 10.1056/NEJMra1609337 10.1182/bloodadvances.2017011502 10.1016/S0140-6736(09)60237-3 10.1155/2012/257086 10.1182/blood-2016-09-737700 10.1097/TP.0b013e3182708e7c 10.18632/oncotarget.20310 10.1016/j.bbmt.2019.11.026 10.1182/blood-2015-09-669846 10.1038/nature15393 10.1038/nprot.2009.86 10.1086/519795 10.1038/bmt.2012.244 10.1006/abio.1999.4293 10.2174/1389200215666140202214012 10.1182/blood-2017-11-817973 10.1038/sigtrans.2017.23 10.1111/bjh.13959 10.1126/science.1098387 10.1038/nature08467 10.1007/s00277-020-03935-5 10.1007/s10549-015-3368-5 10.1002/humu.21641 10.1111/ahg.12293 10.1093/brain/awu408 10.1038/srep18475 10.4049/jimmunol.179.1.647 10.3389/fimmu.2012.00118 10.1038/nature24277 10.1038/onc.2013.587 10.1038/leu.2013.206 10.1161/CIRCULATIONAHA.113.001720 10.1016/j.beha.2008.02.003 10.1016/j.beha.2008.02.002 10.1111/bjh.15456 10.1038/nri2327 10.1182/blood-2013-08-519157 10.1111/j.1365-2443.2011.01529.x 10.4049/jimmunol.1500531 10.1182/blood-2013-11-536888 10.1261/rna.747607 10.1261/rna.075416.120 10.1111/gbb.12127 10.1111/iji.12051 10.1046/j.1365-2141.2003.04676.x 10.1128/MCB.00480-14
Bone Marrow Transplantation; Ansari M, Petrykey K et. al.

Jul 4th, 2021 - The most frequent complication of allogeneic hematopoietic stem cell transplantation is acute Graft versus Host Disease (aGVHD). Proliferation and differentiation of donor T cells initiate inflammatory response affecting the skin, liver, and gastr...

Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogen...
https://doi.org/10.1111/petr.14041
Pediatric Transplantation; Wright M, Rangarajan H et. al.

May 21st, 2021 - Immunosuppressive prophylaxis is usually given to decrease the development of acute graft versus host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Belatacept is a Cytotoxic T-lymphocyte-associated protein 4, bloc...

High dose valaciclovir to prevent cytomegalovirus infection in allogeneic haematopoieti...
https://doi.org/10.1111/tid.13633
Transplant Infectious Disease : an Official Journal of Th... Lam S, Boan P et. al.

May 13th, 2021 - Cytomegalovirus (CMV) infection causes morbidity and mortality after allogeneic haematopoietic stem cell transplantation (HSCT). We investigated whether prophylaxis with high dose valaciclovir is effective at reducing the incidence of clinically s...

Clinical impact of multiple DNA virus infections in nondepleted haploidentical and unre...
https://doi.org/10.1111/tid.13626
Transplant Infectious Disease : an Official Journal of Th... Kerbauy MN, Ribeiro AAF et. al.

Apr 27th, 2021 - Few studies have compared the clinical impact of multiple DNA-virus infections in haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with posttransplant cyclophosphamide (PTCy) and unrelated donor allogeneic hematopoietic stem cel...

see more →

Clinicaltrials.gov  49 results

Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Patients With Steroid Refractory Acute Graft Versus Host Disease
https://clinicaltrials.gov/ct2/show/NCT02524847

Apr 14th, 2020 - Screening: After the informed consent/assent form (ICF) is signed, the screening assessments will be performed in a single visit to establish the eligibility of the patient, based on inclusion and exclusion criteria, as well as aGvHD grading. Sche...

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
https://clinicaltrials.gov/ct2/show/NCT03333486

Mar 17th, 2020 - PRIMARY OBJECTIVES: I. To evaluate the rate of relapse, defined as recurrence of underlying disease or progression of underlying disease, at 1 year in patients who receive haploidentical peripheral blood stem cells (PBSCs) after reduced intensity ...

Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)
https://clinicaltrials.gov/ct2/show/NCT00562497

Mar 10th, 2020 - Subjects will be treated with a total of 6 infusions of investigational agent during the first 4 weeks of the study. Four infusions will be administered during the first two weeks (twice weekly), then two infusions administered during the next two...

Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)
https://clinicaltrials.gov/ct2/show/NCT00136903

Mar 9th, 2020 - Protocol 260 - Subjects will be randomized with equal probability to the treatment arms (2 million cells/kg of Prochymal or 8 million cells/kg of Prochymal) using a stratified block design. The stratification factor is acute GVHD grade. For the pu...

Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention
https://clinicaltrials.gov/ct2/show/NCT02588339

Feb 7th, 2020 - This study will test PANO in combination with tacrolimus/sirolimus (TAC/SIR) for acute GVHD prevention. The purpose of this study is to determine if Panobinostat (PANO) when used in combination with sirolimus and tacrolimus will help reduce the in...

see more →

News  2 results

Morning Break: Teva Pays for Opioid Crisis; Burnout A Real Diagnosis; 60 New Measles Cases
https://www.medpagetoday.com/primarycare/generalprimarycare/80082

May 28th, 2019 - Note that some links may require subscriptions. Teva Pharmaceuticals agreed to an $85 million settlement with Oklahoma over an alleged role in the state's opioid crisis -- which the company denied. (CNN) Incyte announced the FDA expanded indicatio...

Mesoblast stem cell therapy meets goal of pediatric Graft vs. Host study
https://www.reuters.com/article/us-mesoblast-study/mesoblast-stem-cell-therapy-meets-goal-of-pediatric-graft-vs-host-study-idUSKCN1G52W2

Feb 21st, 2018 - (Reuters) - Nearly 70 percent of children with potentially fatal acute Graft Versus Host Disease responded to treatment with an experimental stem cell therapy from Mesoblast Ltd, meeting the primary goal of a late-stage U.S. trial, the Australian ...

see more →